{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:03:30Z","timestamp":1781708610070,"version":"3.54.5"},"reference-count":17,"publisher":"Norwegian Medical Association","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.22.0485","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T01:55:14Z","timestamp":1677030914000},"source":"Crossref","is-referenced-by-count":0,"title":["Diabetic ketoacidosis with SGLT2 inhibitor use \u2013 a patient series"],"prefix":"10.4045","volume":"143","author":[{"given":"Selma","family":"Lejlic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"Holmaas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"L\u00f8v\u00e5s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grethe \u00c5str\u00f8m","family":"Ueland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"ref=1","unstructured":"Norsk legemiddelh\u00e5ndbok. L3.2.6 SGLT2-hemmere. https:\/\/www.legemiddelhandboka.no\/L3.2.6\/SGLT2-hemmere Lest 9.9.2021."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Simes\u00a0BC, MacGregor\u00a0GG. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide. Diabetes Metab Syndr Obes 2019; 12: 2125\u201336. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31686884&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2147%2FDMSO.S212003","DOI":"10.2147\/DMSO.S212003"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Wang\u00a0L, Voss\u00a0EA, Weaver\u00a0J et al. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. Pharmacoepidemiol Drug Saf 2019; 28: 1620\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31456304&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fpds.4887","DOI":"10.1002\/pds.4887"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Thiruvenkatarajan\u00a0V, Meyer\u00a0EJ, Nanjappa\u00a0N et al. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth 2019; 123: 27\u201336. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31060732&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.bja.2019.03.028","DOI":"10.1016\/j.bja.2019.03.028"},{"key":"ref=5","unstructured":"Gosmanov AR, Gosmanova EO, Kitabchi AE. Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. I: Feingold KR, Anawalt B, Boye A et al, red. Endotext. South Dartmouth, MA: MDText.com, Inc., 2000."},{"key":"ref=6","unstructured":"Cosentino\u00a0F, Grant\u00a0PJ, Aboyans\u00a0V et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255\u2013323. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31497854&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093%2Feurheartj%2Fehz486"},{"key":"ref=7","unstructured":"Nilsen T, Vorren S. Metabolsk acidose (ketoacidose) og SGLT2-hemmere \u2013 fortsatt aktuelt. https:\/\/relis.no\/artikler\/27945 Lest 1.10.2021."},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Burke\u00a0KR, Schumacher\u00a0CA, Harpe\u00a0SE. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. Pharmacotherapy 2017; 37: 187\u201394. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27931088&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fphar.1881","DOI":"10.1002\/phar.1881"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Hatlen\u00a0KV, Sharma\u00a0A, Nermoen\u00a0I. Alvorlig ketoacidose hos en pasient med SGLT2-hemmer som diabetesmedisin. Tidsskr Nor Legeforen 2020; 140. doi: 10.4045\/tidsskr.19.0826. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32900172&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4045%2Ftidsskr.19.0826","DOI":"10.4045\/tidsskr.19.0826"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Douros\u00a0A, Lix\u00a0LM, Fralick\u00a0M et al. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study. Ann Intern Med 2020; 173: 417\u201325. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32716707&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.7326%2FM20-0289","DOI":"10.7326\/M20-0289"},{"key":"ref=11","unstructured":"Berg TJ. Diabetisk ketoacidose. https:\/\/indremedisineren.no\/2013\/03\/diabetisk-ketoacidose\/ Lest 9.9.2021."},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Diaz-Ramos\u00a0A, Eilbert\u00a0W, Marquez\u00a0D. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature. Int J Emerg Med 2019; 12: 27. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31488052&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1186%2Fs12245-019-0240-0","DOI":"10.1186\/s12245-019-0240-0"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Sanusi\u00a0I, Sarnowski\u00a0A, Russell-Jones\u00a0D et al. A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition. J Crit Care 2020; 57: 19\u201322. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32007835&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.jcrc.2019.12.007","DOI":"10.1016\/j.jcrc.2019.12.007"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Meyer\u00a0EJ, Gabb\u00a0G, Jesudason\u00a0D. SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications. Diabetes Care 2018; 41: e47\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29440112&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2337%2Fdc17-1721","DOI":"10.2337\/dc17-1721"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Dhatariya\u00a0K. Blood Ketones: Measurement, Interpretation, Limitations, and Utility in the Management of Diabetic Ketoacidosis. Rev Diabet Stud 2016; 13: 217\u201325. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28278308&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1900%2FRDS.2016.13.217","DOI":"10.1900\/RDS.2016.13.217"},{"key":"ref=16","unstructured":"Helsedirektoratet. Blodsukkersenkende behandling og behandlingsm\u00e5l ved diabetes type 2. https:\/\/www.helsedirektoratet.no\/retningslinjer\/diabetes\/behandling-med-blodsukkersenkende-legemidler-ved-diabetes\/blodsukkersenkende-behandling-og-behandlingsmal-ved-diabetes-type-2#metformin-som-forstevalg-ved-diabetes-type-2-referanser Lest 21.12.2022."},{"key":"ref=17","unstructured":"Australian Diabetes Society, New Zealand Society for the Study of Diabetes. ALERT UPDATE January 2020. Periprocedural Diabetic Ketoacidosis (DKA) with SGLT2 Inhibitor Use. https:\/\/diabetessociety.com.au\/documents\/ADS_DKA_SGLT2i_Alert_update_2020.pdf Lest 10.9.2021."}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Diabetisk ketoacidose ved bruk av SGLT2-hemmer \u2013 en pasientserie"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:36:26Z","timestamp":1781706986000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2023\/02\/kort-rapport\/diabetisk-ketoacidose-ved-bruk-av-sglt2-hemmer-en-pasientserie"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2,21]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.22.0485","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]}}}